Lifecare receives notification of intended grant in European patent application and provides update on IP strategy

19 Feb 2026 07:00 CET

Bergen, Norway, 19 February 2026 - Lifecare ASA (LIFE), a MedTech company
developing next-generation implantable continuous glucose monitoring (CGM)
technology, announces that the European Patent Office (EPO) has issued a
communication indicating its intention to grant a patent application filed by
Lifecare Germany GmbH and Scuola Superiore Sant'Anna (Italy).

The pending patent relates to system-level technology relevant to advanced
glucose management solutions. Final grant of this European Patent Application
No. 22740529.7 ("Artificial Pancreas 2021") is expected following completion
of formal grant formalities within a prescribed period.

The intended grant of the patent application strengthens Lifecare's protection
at the system and control level, complementing its chemistry and sensor
architecture portfolio.

Structured and evolving IP strategy

Lifecare operates a structured and dynamic intellectual property strategy
aligned with its long-term platform ambitions.

The Company's IP foundation is built on four complementary pillars:

1. Core proprietary patents covering osmotic pressure-based sensing
principles and sensor architecture.
2. Ongoing patent applications reflecting continued R&D progress.
3. Strategic collaboration-based rights and licensed technologies.
4. Proprietary know-how and system integration expertise protected through
confidentiality and operational control.

This integrated approach reflects Lifecare's position as a platform technology
company, where competitive advantage arises from the interaction between
chemistry, sensing physics, electronics, manufacturing processes and system
integration.

Core granted patents

Lifecare holds several granted patents central to its implantable osmotic
sensing technology, including:

* Apparatus and Method for Measuring Augmented Osmotic Pressure in a Reference
Cavity (granted 2018; expiry 2030) -- core osmotic pressure measurement
principle.
* Interstitial Fluid Osmotic Pressure Measuring Device System and
Method (granted 2011; expiry 2038) -- foundational sensor architecture.
* Fluid composition, method for preparing the composition and use (granted
2024; expiry 2038) -- active fluid chemistry used in sensor applications.

These patents form the backbone of Lifecare's current implantable CGM
development program.

Chemistry development beyond glucose

Lifecare currently has two pending patent applications related to chemistry
compositions, of which one is related specifically to modular compositions.
These filings support the Company's long-term ambition to extend its osmotic
sensing platform beyond glucose monitoring toward broader biomarker detection.

As part of normal portfolio management in research-driven technology
companies, patent applications are continuously refined to reflect ongoing R&D
progress and technical maturation. The current filing builds on advancements
achieved following the initial May 2024 filing and reflects an expanded and
improved technical scope aligned with Lifecare's broader platform ambitions.

This iterative development process is aligned with Lifecare's strategy of
strengthening its platform protection as technical insights evolve.

Expansion of sensing technologies

In parallel with chemistry development, Lifecare has expanded its technology
optionality on the sensing side.

Through its collaboration framework with Johann Wolfgang Goethe-Universität
Frankfurt am Main (GUF), established in 2022, Lifecare holds defined R&D
rights and an option pathway to commercial rights related to Surface Acoustic
Wave (SAW) sensor technology.

While Lifecare's first-generation product utilizes commercially available
piezoresistive pressure sensors, both SAW and Nano Tunneling Resistor (NTR)
technologies represent future miniaturisation and sensitivity pathways.

Together, these initiatives reflect a deliberate strategy to expand the
Company's platform in two dimensions:

* Broader chemistry capable of detecting additional biomarkers.
* Multiple sensing mechanisms capable of translating biochemical changes into
measurable signals.

Lifecare considers its patent portfolio, collaborative rights, and proprietary
know-how to be aligned with the Company's current development stage and
long-term commercial strategy.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

More information:
Access the news on Oslo Bors NewsWeb site

666168_Lifecare receives notification of intended grant in European patent application and provides update on IP strategy.pdf